Trial Profile
IMMUNIZATION TO PREVENT ACUTE COPD EXACERBATIONS (IMPACE STUDY)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Acronyms IMPACE
- Sponsors Pfizer
- 25 Apr 2023 Status changed from completed to discontinued.
- 06 Mar 2023 Status changed from recruiting to completed.
- 19 Apr 2021 Planned End Date changed from 30 Dec 2022 to 10 Jan 2023.